Which has stronger valuation and earnings, VOR or RNAC?

Vor Biopharma has higher earnings, but lower revenue than Cartesian Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Cartesian Therapeutics $2.80M 82.68 -$130.30M -$5.90 N/A

Is VOR or RNAC more profitable?

Vor Biopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Cartesian Therapeutics -8,550.65% N/A -28.25%

Which has better valuation and earnings, RNAC or IVA?

Cartesian Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cartesian Therapeutics $2.80M 82.68 -$130.30M -$5.90 N/A Inventiva $4.48M 206.64 -$400.67M N/A N/A

Is RNAC or IVA more profitable?

Inventiva has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics -8,550.65% N/A -28.25% Inventiva N/A N/A N/A

Cartesian Therapeutics (RNAC) Competitors

$7.88 -0.04 (-0.51%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$8.28 +0.40 (+5.01%)

As of 07/24/2026 07:34 PM Eastern

Compare

RNAC vs. KURA, VOR, PHAR, IVA, and ANNX

Should you buy Cartesian Therapeutics stock or one of its competitors? MarketBeat compares Cartesian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cartesian Therapeutics include Kura Oncology (KURA), Vor Biopharma (VOR), Pharming Group (PHAR), Inventiva (IVA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to Kura Oncology?

Cartesian Therapeutics (NASDAQ:RNAC) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Kura Oncology has a net margin of -411.19% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Kura Oncology	-411.19%	-141.95%	-43.28%

Cartesian Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	82.68	-$130.30M	-$5.90	N/A
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A

Cartesian Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Kura Oncology had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for Kura Oncology and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.89 beat Kura Oncology's score of 1.12 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Very Positive
Kura Oncology	Positive

87.0% of Cartesian Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cartesian Therapeutics currently has a consensus price target of $32.60, suggesting a potential upside of 313.71%. Kura Oncology has a consensus price target of $25.46, suggesting a potential upside of 145.06%. Given Cartesian Therapeutics' higher probable upside, equities research analysts plainly believe Cartesian Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Cartesian Therapeutics beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Vor Biopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

In the previous week, Vor Biopharma had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.89 beat Vor Biopharma's score of 1.10 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Vor Biopharma	Positive
Cartesian Therapeutics	Very Positive

Vor Biopharma has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Vor Biopharma presently has a consensus target price of $42.25, suggesting a potential upside of 119.37%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 313.71%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vor Biopharma has higher earnings, but lower revenue than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Cartesian Therapeutics	$2.80M	82.68	-$130.30M	-$5.90	N/A

Summary

Vor Biopharma beats Cartesian Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Pharming Group?

Cartesian Therapeutics (NASDAQ:RNAC) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Cartesian Therapeutics presently has a consensus target price of $32.60, indicating a potential upside of 313.71%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 204.11%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Pharming Group had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for Pharming Group and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.89 beat Pharming Group's score of 0.54 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Very Positive
Pharming Group	Positive

Pharming Group has a net margin of 3.30% compared to Cartesian Therapeutics' net margin of -8,550.65%. Pharming Group's return on equity of 4.64% beat Cartesian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Pharming Group	3.30%	4.64%	2.55%

Cartesian Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	82.68	-$130.30M	-$5.90	N/A
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.78

Summary

Cartesian Therapeutics and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Inventiva?

Cartesian Therapeutics (NASDAQ:RNAC) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Inventiva has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Inventiva	N/A	N/A	N/A

Cartesian Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cartesian Therapeutics presently has a consensus price target of $32.60, indicating a potential upside of 313.71%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 271.20%. Given Cartesian Therapeutics' higher probable upside, equities research analysts plainly believe Cartesian Therapeutics is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Cartesian Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	82.68	-$130.30M	-$5.90	N/A
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A

In the previous week, Inventiva had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.89 beat Inventiva's score of 0.53 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Very Positive
Inventiva	Positive

Summary

Inventiva beats Cartesian Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Annexon has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Annexon currently has a consensus price target of $15.33, suggesting a potential upside of 193.74%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 313.71%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cartesian Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Cartesian Therapeutics	$2.80M	82.68	-$130.30M	-$5.90	N/A

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Annexon has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

In the previous week, Annexon had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for Annexon and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.89 beat Annexon's score of 0.96 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Annexon	Positive
Cartesian Therapeutics	Very Positive

Summary

Cartesian Therapeutics beats Annexon on 10 of the 14 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$232.70M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.34	21.11	27.00	23.71
Price / Sales	82.68	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-1.62	7.88	10.28	6.07
Net Income	-$130.30M	$23.81M	$3.60B	$331.84M
7 Day Performance	-4.60%	-3.79%	-1.25%	-1.53%
1 Month Performance	-11.76%	-2.59%	-0.35%	-2.46%
1 Year Performance	-40.89%	32.85%	18.41%	13.66%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	2.8599 of 5 stars	$7.88 -0.5%	$32.60 +313.7%	-41.5%	$232.70M	$2.80M	N/A	64	Positive News
KURA Kura Oncology	3.4733 of 5 stars	$10.89 +2.0%	$25.46 +133.8%	+60.6%	$948.11M	$67.48M	N/A	130	News Coverage Positive News
VOR Vor Biopharma	2.8316 of 5 stars	$20.05 +14.9%	$42.25 +110.7%	-55.6%	$945.54M	N/A	N/A	140	Positive News
PHAR Pharming Group	2.5307 of 5 stars	$13.16 +0.4%	$38.33 +191.3%	+25.4%	$927.90M	$376.13M	82.26	280	Upcoming Earnings Short Interest Increase
IVA Inventiva	2.3468 of 5 stars	$4.48 +1.6%	$16.56 +269.5%	+35.8%	$917.03M	$5.07M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. KURA, VOR, PHAR, IVA, and ANNX

How does Cartesian Therapeutics compare to Kura Oncology?

Summary

How does Cartesian Therapeutics compare to Vor Biopharma?

Summary

How does Cartesian Therapeutics compare to Pharming Group?

Summary

How does Cartesian Therapeutics compare to Inventiva?

Summary

How does Cartesian Therapeutics compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. KURA, VOR, PHAR, IVA, and ANNX

How does Cartesian Therapeutics compare to Kura Oncology?

Is RNAC or KURA more profitable?

Which has stronger valuation and earnings, RNAC or KURA?

Which has more volatility and risk, RNAC or KURA?

Does the media refer more to RNAC or KURA?

Do institutionals and insiders hold more shares of RNAC or KURA?

Do analysts prefer RNAC or KURA?

Summary

How does Cartesian Therapeutics compare to Vor Biopharma?

Is VOR or RNAC more profitable?

Does the media favor VOR or RNAC?

Which has more risk and volatility, VOR or RNAC?

Do analysts recommend VOR or RNAC?

Do institutionals & insiders have more ownership in VOR or RNAC?

Which has stronger valuation and earnings, VOR or RNAC?

Summary

How does Cartesian Therapeutics compare to Pharming Group?

Do analysts rate RNAC or PHAR?

Does the media favor RNAC or PHAR?

Is RNAC or PHAR more profitable?

Which has more volatility & risk, RNAC or PHAR?

Do institutionals & insiders hold more shares of RNAC or PHAR?

Which has preferable valuation & earnings, RNAC or PHAR?

Summary

How does Cartesian Therapeutics compare to Inventiva?

Is RNAC or IVA more profitable?

Which has more volatility and risk, RNAC or IVA?

Do insiders and institutionals hold more shares of RNAC or IVA?

Do analysts rate RNAC or IVA?

Which has better valuation and earnings, RNAC or IVA?

Does the media refer more to RNAC or IVA?

Summary

How does Cartesian Therapeutics compare to Annexon?

Is ANNX or RNAC more profitable?

Do analysts rate ANNX or RNAC?

Which has better valuation & earnings, ANNX or RNAC?

Do insiders and institutionals hold more shares of ANNX or RNAC?

Which has more risk and volatility, ANNX or RNAC?

Does the media favor ANNX or RNAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools